$TXAC News
Last published 6y ago
- 6y agoTXACVor Biopharma Appoints David Lubner to Its Board of DirectorsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of David Lubner, a senior finance executive with over 25 years of experience, to Vor’s Board of Directors.
- 6y agoPSTHPSACUDFHTUHPX+7ICR, the Leading SPAC Advisor, Publishes Mid-Year 2020 SPAC UpdateBusiness WireNEW YORK--(BUSINESS WIRE)--ICR, a leading strategic communications and advisory firm, today released its Q2 2020 SPAC Update report: “Are SPACs Driving the Democratization of IPOs?” SPAC IPO issuance has accelerated as improved deal structures, high quality SPAC sponsors and blue chip institutional investors converge. Strong SPAC IPO activity has resulted in 121 public SPACs holding more than $34 ...
- 6y agoTXACTherapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Closing of $135.7 Million Initial Public Offering, Including the Full Exercise of the Underwriter’s Option To Purchase Additional SharesBusiness WireBOSTON--(BUSINESS WIRE)--Therapeutics Acquisition Corp. (Nasdaq: TXAC) (the “Company”) announced today that on July 10, 2020 it closed its initial public offering of 13,570,000 shares of Class A common stock, including 1,770,000 shares issued pursuant to the exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per share, resulting in gross proceeds of $135 ...